Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
ROCEPHIN KIT is a fixed-dose combination injectable containing ceftriaxone sodium (a third-generation cephalosporin) and lidocaine (a local anesthetic). It is used to treat bacterial infections across multiple body systems by inhibiting bacterial cell wall synthesis, with lidocaine reducing injection site pain. The kit formulation enables convenient reconstitution for intramuscular or intravenous administration.
Product approaching loss of exclusivity with moderate competitive pressure (30 competitor intensity); team focus likely shifting to legacy management and cost optimization rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on ROCEPHIN KIT in a LOE-approaching environment offers limited career growth but valuable experience in mature product management, formulary defense, and transition planning. Professionals on this team should expect focus on margin protection, generic containment strategies, and potential product discontinuation planning rather than expansion.
Worked on ROCEPHIN KIT at Roche? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo